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RESEARCH IN CONTEXT  
Evidence before this study 
It is widely accepted that COPD is substantially under-diagnosed worldwide. Mass population 
screening with spirometry is not recommended although early identification of undiagnosed patients 
with clinical disease is generally supported because COPD has significant patient, healthcare and 
societal burden which could potentially be lessened through timely diagnosis. A comprehensive 
systematic review of the effectiveness of case-finding studies, published in 2015, revealed 39 
published studies but few included a comparator arm. Only one RCT has compared a case-finding 
approach with routine care to identify clinically significant COPD, identifying that opportunistic 
administration of a screening questionnaire at practice visits was twice as effective as routine care, but 
non-comparative studies suggest that high yields could be achieved from active case finding with 
mailed questionnaires to high risk patients. No previous trial has compared the clinical and cost-
effectiveness of alternative approaches to case-finding in a real-life primary care setting. 
 
Added value of this study 
TargetCOPD is the first randomised controlled trial to evaluate the effectiveness and cost-
effectiveness of active case-finding for COPD compared with opportunistic case finding and to 
compare these approaches with routine care. Among 54 general practices, we found that when 
targeting ever smokers aged 40-79 years, active case finding was more than twice as effective as 
opportunistic case finding, and that together, these targeted approaches were over seven times as 
effective as current routine care. Active case finding was also more cost-effective than opportunistic 
case finding. 
 
Implications of all the available evidence 
In a real-life setting, active case-finding comprising an initial mailed questionnaire followed by 
spirometry should be recommended for identifying undiagnosed COPD in primary care. An important 
proportion of these previously undiagnosed patients have significant breathlessness and earlier 
identification and management with effective treatments including inhalers and pulmonary 
rehabilitation has the potential to improve their health. This trial provides the evidence for guidelines 
which was previously lacking.   
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SUMMARY 
Background 
Many individuals with chronic obstructive pulmonary disease (COPD) remain undiagnosed 
worldwide.  Healthcare organisations are implementing case-finding programmes without good 
evidence of which are the most effective and cost-effective approaches. 
 
Methods 
This cluster randomised controlled trial (RCT) among general practices in the West Midlands, UK, 
compared the effectiveness and cost-effectiveness of two alternative approaches to targeted case 
finding with routine practice among ever-smokers aged 40-79 years without a prior recorded 
diagnosis of COPD.  Patients in targeted practices were randomised via their households to receive 
screening questionnaires at GP consultations (opportunistic) or additionally by mail (active) and 
compared with the routine care arm. Respondents reporting relevant respiratory symptoms were 
invited for post-bronchodilator spirometry. Primary outcomes at 12 months among all eligible 
participants were probability of detecting a new case of COPD for each treatment arm and cost per 
new COPD diagnosis (defined as post-bronchodilator FEV1/FVC<0.7 among patients with symptoms 
or a new diagnosis on their GP record). Multiple logistic and Poisson regression were used to estimate 
effect sizes. Costs were obtained from the trial. This trial is registered as an International Standard 
Randomised Controlled Trial, number  ISRCTN14930255. 
Findings 
54 diverse general practices (74,818 eligible patients) were randomised and completed the trial 
(August 2012-June 2014). Overall 1278/32,789 (3.9%) cases were newly detected in the targeted arm 
compared with 337/42,029 (0.8%) in the routine practice arm, adjusted OR 7.45 (95%CI 4.80, 
11.55)(p<0.001). Active case-finding was more effective than opportunistic (adjusted OR 2.34 (2.06, 
2.66)(p<0.001), adjusted risk difference 2.9 per 100 patients (95%CI 2.3, 3.6)), and more cost–
effective (£333 vs £376 per case detected).  
Interpretation 
In this well-established primary care system, routine practice identified few new cases. An active 
targeted approach including mailed screening questionnaires prior to spirometry is a cost-effective 
way to identify undiagnosed patients and has the potential to improve their health.  
Funding: National Institute for Health Research  
Key words: COPD; case-finding; screening; primary care; respiratory questionnaire; spirometry; 
cluster RCT; effectiveness; cost-effectiveness 
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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a common long-term respiratory condition with 
high healthcare and societal burden1 with estimated annual costs of $50 billion (2010) to the US1 and 
€48.6 billion (2011) to the EU economy2. Worldwide, the diagnosed prevalence is estimated to be 
about 5% of adults over 40 years,3 but at least an equivalent number with significant symptomatic 
COPD remain undiagnosed and could potentially benefit from effective interventions.4-5 There is a 
worldwide drive to identify these “missing millions”6-9 and many healthcare organisations are 
implementing case-finding programmes, although without good evidence of which are the most 
effective and cost-effective approaches. 
There are numerous reports of uncontrolled studies of case-finding, with heterogeneous populations, 
interventions and case definitions.10 However, only one published RCT, within family medical 
practices in the US, has evaluated a systematic approach to identifying previously undiagnosed 
clinical COPD compared with usual care.11 This demonstrated that initial opportunistic administration 
of a screening questionnaire was twice as effective as usual care in identifying new cases of COPD. 
Other uncontrolled studies have suggested that sending a screening questionnaire by post prior to 
spirometry assessment is a promising alternative method,10 but the comparative effectiveness and 
cost-effectiveness of the two approaches has not been tested. 
Modelling of observational data suggested that an active approach (including both mailed 
questionnaires and opportunistic administration) could be twice as effective as an opportunistic-only 
approach, and identify patients with significant potential to benefit.4 Here we present the findings 
from a large pragmatic cluster RCT in a UK primary care setting, to evaluate fully the effectiveness 
and cost-effectiveness of these two methods of identifying undiagnosed COPD.  
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METHODS 
Study design 
TargetCOPD was a pragmatic cluster RCT comparing an active and an opportunistic targeted 
approach to case finding for undiagnosed COPD with routine practice in primary care (Figure 1).12 
UK ethical and research governance approvals were obtained (Ref:11/WM/0403).  
 
Practice and participant recruitment 
All 354 general practices (GPs) (family medical practices) in the Birmingham and Black Country 
region of the West Midlands, UK were invited to take part. Automated computer searches of 
electronic health records (EHR)(Appendix 1) identified ever smokers aged 40 to 79 years without a 
prior diagnosis of COPD. Physicians then excluded at their discretion those they considered 
unsuitable (for example those unable to give informed consent, having terminal illness, being 
pregnant). The remaining patients were classed as “approved” to receive a screening questionnaire. 
 
Randomisation and masking  
General practices were initially randomised in three phases using variable block size by the trial 
statistician into targeted case finding or routine practice. Cluster randomisation was preferred so that 
healthcare staff in the routine care arm did not change their usual practice for control patients because 
of raised awareness about case finding, and because we wanted to assess a whole practice 
organisational approach which could be undertaken in “real-life”.  A published algorithm for cluster 
randomised trials was used to balance key practice characteristics (deprivation (Index of Multiple 
Deprivation score of the practice), ethnicity (%white patients), practice list size, age (% aged > 45 
years) and proportion of patients on the COPD register13) with stratification for linked practices. 12,14 
Practices were unaware of their allocation until baseline patient data had been provided and they had 
agreed to commence the study. Within the targeted arm, individual households were subjected to 
block randomisation (block size 20) using a random number generator (automatically applied when 
participants from each practice were uploaded to the trial database) to active or opportunistic case 
finding, ensuring that patients from the same household were allocated the same intervention to avoid 
contamination. The allocation ratio was 1:1 for randomisation of both general practice and 
households.  Data processing was computerised and research assistants carrying out spirometry 
assessments were unaware of the allocation. 
 
Interventions 
The case-finding intervention was applied for 12 months in each practice, with a staggered start 
(August 2012 – June 2013). 12 practices (6 targeted, 6 routine) formed an internal pilot phase to test 
procedures.  
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Targeted case finding arm 
Eligible patients were allocated to receive a brief screening questionnaire (Appendix 2) in either of 
two ways: 
(a) Opportunistic: patients’ electronic health records (EHR) were flagged to prompt handing out 
the questionnaire during any visit to their general medical practice. 
(b) Active: In addition to opportunistic distribution, the screening questionnaire was mailed to 
patients’ homes (with reply-paid envelope). Reminders were sent after 4 and 8 weeks.  
EHR prompts were removed after receipt of the questionnaire.  All participants in the targeted arm 
were provided with patient information leaflets and a standard letter of invitation from their GP and 
respondents were considered to have implied consent by returning their questionnaire with their 
personal details. 
The questionnaire was piloted by our patient advisory group. 
 
Routine practice arm 
The GPs in the routine practice arm were expected to follow UK guidance which recommends that 
patients aged >35 years should be investigated for COPD with spirometry if they present with chronic 
cough or phlegm, exertional breathlessness or wheeze.15 National QOF data show that >80% of 
patients newly diagnosed with COPD receive confirmatory spirometry within 12 months.13 Consent 
was not required from patients in the routine care arm as we did not obtain patient-identifiable data. 
 
Spirometry diagnostic assessments 
Patients in the targeted arm who responded to the screening questionnaire and reported any of the 
following respiratory symptoms (chronic cough/phlegm for >3 months for at least 2 years, wheeze in 
the last 12 months or dyspnoea of MRC grade 2 or more) were invited to attend their GP practice for 
confirmatory spirometry. Attendees provided signed informed consent at the start of the assessment. 
Post-bronchodilator spirometry was undertaken according to ATS/ERS 2005 guidelines16 using an 
ultrasonic flow head (Spiroson-AS, ndd, Zurich) with bespoke software (MRMiller) and carried out 
by blinded, trained research assistants with immediate visual quality control monitoring and feedback. 
Every trace was over-read and quality of blows graded according to standard criteria.17  Patients also 
completed a short questionnaire to ascertain out of pocket expenses for attendance (Appendix 3) and 
health status (EQ-5D).18 Patients’ height was measured to the nearest cm using a portable stadiometer 
(or estimated using arm-span if necessary). 
 
Outcomes  
Primary outcomes were the percentage of the eligible population diagnosed with COPD within one 
year, and cost per additional case identified in each arm, comparing (1) active and opportunistic case 
finding, then (2) targeted case finding and routine care.  Secondary outcomes were feasibility (process 
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measures including uptake and resource needs) and efficiency (number needed to target to identify 
one person likely to benefit). 
 
Diagnosing COPD 
New cases in the targeted arm were identified either through the trial spirometry assessment visit 
(post-bronchodilator FEV1/FVC<0.7 in the presence of respiratory symptoms, in line with 
recommended UK guidelines15 ) or through the EHR using automated searches with clinical (Read) 
codes (Appendix 1), to ensure fair comparison with the routine arm. New cases in the routine arm 
were identified from the EHR only as they did not receive a trial spirometry assessment. In sensitivity 
analyses we used the “Lower Limit of Normal” (LLN) definition (GLI 2012 equations19) to define 
airflow limitation.  
 
Additional data collection  
Additional data from the EHR were collected at baseline and 12 months to ascertain patient 
characteristics, medical conditions and study outcomes. In order to estimate opportunistic 
questionnaire distribution in the targeted arm, 30 patients from each of the opportunistic and active 
arms in each practice were randomly sampled to ascertain whether EHR prompts had been removed. 
 
Sample size  
The significance level for multiple testing was adjusted to provide a total of 5% significance level 
across the two primary effectiveness outcomes: 0.25% for the opportunistic vs active comparison, and 
4.75% for the targeted vs routine care comparison. The sample size calculation was computed from 
estimates presented in our published model of case finding4, which used data from the Health Survey 
for England and published literature to estimate values for different stages of the process, and 
provided in detail in our protocol.12 
For the opportunistic vs active comparison, we assumed 50% allocated to the active arm would 
respond; of the remaining patients 91% would visit their GP at least once in 12 months, 50% would be 
offered the questionnaire and 90% of these would fill it out. In the Opportunistic arm we assumed 
50% would be offered the questionnaire and of these 90% would complete questionnaires. Of all 
responders to the questionnaire in both arms, we assumed 48% would report symptoms and be invited 
to spirometry, of whom 70% would attend and 17% of these would have COPD. This would lead to 
yields of 2.3% in the opportunistic and 4.0% in the active arms. At a 0.25% significance level, 3904 
patients/arm were required to detect this difference with 90% power. 
 
For the targeted vs routine care comparison, the proportion of new COPD cases detected in the 
targeted group (averaged across both active and opportunistic arms) was assumed to be 3.15%. The 
proportion of new COPD cases detected in the routine care group was assumed to be 0.75%. At the 
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4.75% significance level, with 80% power, this led to an unadjusted sample size required of 545 per 
group, in order to detect a difference of 2.4% between targeted and routine care arms. We expected 
~40% of a practice population to be aged 40-79yrs with 57% of these being ever smokers without a 
previous diagnosis of COPD. Assuming therefore a conservative 1000 eligible patients per practice of 
average list size 6000, and adjusting for clustering of patients within practices, assuming a 
conservative ICC of 0.05 the sample size required was 27,768 per arm, equivalent to 28 practices per 
arm. 
 
Statistical analyses  
All analyses were undertaken in Stata 13 (StataCorp LP, Texas). The process measures such as 
questionnaire response rates were presented using simple descriptive statistics. For the primary 
outcomes, all models used outcomes for individual participants and were adjusted for practice level 
deprivation (IMD – index of multiple deprivation), patient ethnicity and age, as pre-defined in the 
protocol.12  
To compare opportunistic and active arms, logistic regression was used including a fixed effect for 
each practice (adjustment for household made little difference to results therefore was not presented). 
Adjusted relative risks and risk differences were also estimated using Poisson regression with robust 
standard errors,20 and from these, numbers needed to target (NNT) were computed. The analysed 
population included only those patients approved by their GP to receive a screening questionnaire.  
To compare targeted and routine care, the same approach was taken but multilevel regression models 
were used (logistic and Poisson with robust standard errors) with a separate random effect for targeted 
and routine practices, to allow for clustering and between-practice heterogeneity in the underlying log 
odds of COPD case-detection for each arm. In this case, the analysed population included all eligible 
patients meeting the entry criteria. An estimate of the ICC was obtained by fitting a multilevel linear 
null model. 
 
Economic analyses 
The base-case analysis estimated the cost per additional case detected with active and opportunistic 
case-finding compared with routine care, taking a healthcare perspective and using multi-level 
modelling in line with the main trial analysis.12 Incremental cost-effectiveness ratios were calculated, 
by dividing the difference in mean per patient costs by the difference in mean patient outcomes (cases 
detected). A bottom-up approach was employed to cost the case-finding strategies, using data 
collected within the trial (Table 1). Standard NHS unit costs and trial-specific costs were applied to 
calculate the costs of each process (Appendix 4) using 2013 prices.  Spirometry costs were calculated 
assuming that it would be provided by an NHS outreach service. Reusable equipment was amortised 
over five-years, and training costs spread over three years, using a discount rate of 3.5%, Costs 
incurred by patients and their families to attend spirometry assessments (including travel, care and 
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cost of time off work) were included in a sensitivity analysis and obtained by patient self-report while 
attending the assessment. Time spent away from paid work was valued at the average national wage 
rate. Costs incurred after COPD was confirmed were not considered in this analysis. Sensitivity 
analyses were also undertaken to estimate the cost-effectiveness of different models of care and 
alternative case-finding scenarios. Three alternative models of care were considered including a GP-
led model, a community-led model and a secondary-care model (Appendix 4).  
 
This trial is registered as an International Standard Randomised Controlled Trial, number  
ISRCTN14930255. 
Role of the funding source 
The funder had no role in study design, data collection, data interpretation, or writing of the report. 
The corresponding authors had full access to all the data in the study and had final responsibility for 
the decision to submit for publication. 
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RESULTS 
56 GP practices agreed to participate (fig S1), but two withdrew before randomisation.  Practices took 
part between August 2012 and June 2014. No practices were lost-to-follow-up by one year.  
Practice and participant characteristics were well balanced between targeted case finding and routine 
care (Table 2) although the routine arm (n=42,029 patients) was larger than the targeted arm 
(n=32,811) with some slight differences in distribution of smoking status and participants living in 
shared households. Practice characteristics were broadly representative of those in the Birmingham 
and Black Country region with a wide range of socioeconomic deprivation, practice size and 
populations served. 
 
Targeted arm: opportunistic vs active case finding nested study 
For the nested trial within the targeted arm, comparing opportunistic with active case finding, of a 
total of 32,811 patients, 30,787 were approved to be allocated a screening questionnaire by GPs.  
15,393 were allocated to the opportunistic, and 15,394 to the active arm (figure S2), and 22 formally 
withdrew from the trial.  Patient characteristics were similar between arms (Table S1). Values used 
below are for those analysed, excluding those withdrawing use of their data. 
 
In the opportunistic arm, 89% (13718/15387) of patients consulted their GP/primary care professional 
within the 12 month period (see figure 1).  Sampling of record-flags across practices suggested that 
screening questionnaires were distributed to 48.5% (95%CI 45.0, 52.0) of eligible patients in the 
opportunistic arm (range 0% to 100%). All eligible patients in the active arm received a questionnaire. 
 
In the opportunistic arm, 1973/15387 (12.8% of eligible patients) returned their questionnaire (range 
0-30.8%).  In the active arm, 5808/15387 (37.8%) returned screening questionnaires, the majority 
(5042/15387, 86.8% of the total) after receiving it through the post rather than at the medical practice. 
Responses increased following each reminder; (2312/15378 (13.7%) after the initial invite, 
1624/15378 (10.6%) after the first and 1086/15378 (6.7%) after the second reminder), and varied by 
GP practice (range 22.3% to 53.5%)(Table S2).  
 
Among responders to the screening questionnaire, 4341/7781 (55.8%) reported symptoms triggering 
an invitation for spirometry assessment (opportunistic arm; 3264/5808 54.6%, active arm: 1077/1973 
56.2%).  3142/7781 (40.4%) reported dyspnoea of MRC Grade 2 or worse, 2989/7781 (38.4%) 
wheeze in the past 12 months, 926/7781 (11.9%) chronic cough and 727/7781 (9.3%) chronic phlegm 
(Table S3).  Chronic cough (752/5808 13.0% vs 174/1973 8.8%) and chronic phlegm (589/5808 
10.1% vs 138/1973 7.0%) were more commonly reported in the active arm, although the prevalence 
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of dyspnoea and wheeze was similar in both arms. Non-responders were more likely to be younger, 
current smokers and of non-White British ethnicity than respondents. 
 
543/1077 (50.4%) participants with respiratory symptoms in the opportunistic, and 2065/3264 
(63.3%) in the active arm attended a spirometry assessment (figure S2). 93.8% of blows met Grade A-
C quality criteria.17  851/2608 (32.6%) of assessed patients had airflow obstruction using the 
FEV1/FVC<0.7 criteria, and 529/2608 (20.3%) using GLI equations. 
 
After one year, a larger percentage of new COPD cases were detected in the active (822/15387; 5.4%) 
compared with the opportunistic arm (n=370/15378; 2.4%), giving an adjusted OR of 2.34 (95%CI 
2.06, 2.66)(p<0.001) and, assuming a baseline risk of 2.4%, an adjusted risk difference of 2.9 per 100 
patients (95%CI 2.3, 3.6)(table 3). This effect varied across practices (figure S3) although all but one 
had an OR estimate in favour of the active group. 35 (95% CI 27.8, 43.5) screening questionnaires 
would need to be mailed to identify one extra COPD patient. 
 
Among newly identified patients, severity of airflow obstruction was similar in both arms (table 3), 
with 819/851 (96.2%) classified as either mild (459/851; 53.9%) or moderate (360/851; 42.3%). 
231/851 (27.1%) reported dyspnoea of MRC grade 3 or more, and 300/851 (35.3%) were current 
smokers.  
 
In sensitivity analyses using GLI equations, 607/15378 (3.9%) and 303/15387 (2.0%) of the targeted 
population had undiagnosed COPD identified in the active and opportunistic arms respectively 
(adjusted OR 2.07 (1.80, 2.38)(p<0.001).  
 
Targeted case finding vs routine care 
In the routine arm, 337/42029 new cases of COPD were diagnosed after one year (0.8% of eligible 
patients) (Table 4) and considering all eligible patients (even if not approved for receiving a trial 
screening questionnaire), a total of 1278/32789 (3.9%) in the targeted arm. After adjusting for age, 
IMD score, ethnicity and clustering of practices (ICC=0.02), the likelihood of detecting undiagnosed 
COPD was much greater in the targeted arm (adjusted OR 7.45 (95%CI 4.80, 11.55), p<0.001). With 
a baseline risk of 0.8%, the adjusted risk difference was 4.9 per 100 patients (3.0, 7.7)) and therefore 
21 (13.0, 33.3) patients would require targeting with a screening questionnaire (NNT) to identify one 
new case.   
 
Sensitivity analyses using the lower limit of normal definition of COPD with GLI equations19 
attenuated the effect in the targeted arm (996/32789 new cases; 3.0% yield), although the approach 
remained significantly better than for the routine arm: adjusted OR=5.41 (3.47, 8.43)(p<0.001). 
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Economic analyses 
Compared with routine care, active case finding was more cost-effective (£333 ($476) per additional 
case detected) than opportunistic case finding (£376) ($538) (table 5). The incremental cost-
effectiveness ratio (ICER) for active case finding was £573($889) per additional case detected 
compared with opportunistic. Including patient-incurred costs made little difference to the results 
although alternative GP-led or Tariff models (where spirometry would be conducted in hospital 
outpatient appointments) were more expensive. ICERs for both opportunistic and active case-finding 
were lower when older age-groups or current smokers only were targeted, although at the expense of 
identifying many fewer cases. If no reminders were sent to patients, the opportunistic approach would 
be more cost-effective than the active approach. However, in every alternative scenario, active case 
finding identified more new cases than opportunistic case finding. 
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DISCUSSION  
Identifying undiagnosed COPD remains an important priority worldwide. Despite little available 
evidence, national guidelines recommend opportunistic case-finding in the primary care setting.15 
However, in our large, generalisable, “real-life” RCT, very few new cases were identified in routine 
care. As expected, we demonstrated that a systematic targeted approach was markedly more effective 
than routine care at identifying new cases of COPD (adjusted OR 7.45 (95%CI 4.80, 11.55)). More 
importantly, we found that an active case-finding approach was twice as effective as opportunistic 
case-finding (adjusted OR 2.34 (2.06, 2.66)), and more cost–effective (£333 vs £376 per case 
detected). 
In contrast to many previous studies, we sought clinical cases of COPD confirmed with spirometry. 
There is only one other relevant trial, undertaken among family medical practices in the US, which 
compares the effectiveness of a case-finding approach against usual care, although it did not confirm 
COPD with spirometry and may not be comparable to the UK or similar primary care settings.11 
Consistent with our findings, this trial demonstrated that a structured approach to case-finding using a 
screening questionnaire administered opportunistically was more effective than routine care in 
identifying new cases of COPD, although the effect size was smaller (OR=2.38) and diagnostic yield 
in routine care was lower than in our study (0.49% vs 0.8%).11 In the literature there have also been 
many uncontrolled evaluations of case finding approaches for COPD with similar yields to our case-
finding arm.10  However, other than our pilot study,21 our trial is the first to evaluate the most cost-
effective method of administering an initial screening questionnaire, and to compare the results with 
routine care. The findings from this trial also confirm the results from our published model,4 which 
suggested the likely superiority of active over opportunistic case finding.  
 
In the active arm, around a third of eligible participants responded to the postal screening 
questionnaires, which was consistent with a trial in the Netherlands which compared two methods of 
processing a postal screening questionnaire,22 and with uncontrolled studies described in our 
systematic review10. The response rate in our opportunistic arm was lower than we expected from our 
model4 but similar to our pilot study21 (13% on average across the practices and a maximum of 31%). 
Unlike other studies10, our uptake rates include the whole eligible population as the denominator. It is 
also likely that our study reflects real life in busy UK primary care, where opportunistic 
administration of a questionnaire might not always be possible. Opportunistic response rates would 
need to be at least 40% (figure 1) to reach the yield observed with the active approach.  
Our work builds on other published evaluations. A particularly relevant programme of work in the 
Netherlands – Detection, Intervention and Monitoring of COPD and Asthma (DIMCA) programme, 
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which began in 1991sought to detect subjects with signs of COPD and asthma at an early stage using 
a two-stage process of screening and monitoring, finding that 52% of adults aged 25-70 had early 
signs and symptoms of COPD or asthma, and 7.7% overall showed persistently decreased lung 
function or increased bronchial hyper-responsiveness.23,24  
Our finding that newly identified cases tended to have mild or moderate airflow obstruction was in 
keeping with previous case-finding studies10  and newly case-found patients were generally less severe 
than patients newly diagnosed in primary care.25 Nevertheless, in accordance with our model, the 
majority of new cases could potentially benefit from inhalers,26,27 self-management support,28 
smoking cessation29 and vaccinations.30 A substantial proportion (27%) also had significant 
breathlessness with potential to benefit from pulmonary rehabilitation.31 However, it is important to 
note that the published evidence available on the effectiveness of these interventions may not directly 
apply to milder or case-found COPD patients for whom new studies are urgently needed.32  
A notable strength of our trial was the achievement of high quality post-bronchodilator spirometry for 
COPD diagnosis. We have demonstrated the feasibility of undertaking excellent quality spirometry 
outside of a specialist setting with previously untrained staff, implementing a rigorous training 
programme and quality control system. 
However, there were a number of practical difficulties. Using electronic searches of primary care 
records to identify ever smokers without prior COPD diagnoses was not always accurate. We 
acknowledge that there were more never smokers reported in the routine arm, which, as shown in 
sensitivity analyses (OR removing never smokers= 6.33 (4.12, 9.74)), may have slightly exaggerated 
the effect size. Although we aimed to exclude patients with a prior diagnosis of COPD using 
information from EHR records, 4.6% of the respondents to the screening questionnaire self-reported 
ever having been told that they had COPD, chronic bronchitis or asthma. However, this is unlikely to 
have influenced the direction of the results as only 10% of those newly diagnosed in our targeted arm 
reported having these conditions. Also, because of the large volume of participants, we were only able 
to invite patients for spirometry once, relying on reminder text messages (where possible) for those 
who did not attend to contact the office for further appointments. This led to lower attendance rates 
than expected, but was unlikely to make a substantial difference to the comparative effect size. 
Furthermore, we found it difficult to know with certainty what proportion of opportunistic 
questionnaires was administered, but it was clearly sub-optimal.  Nevertheless, this was a pragmatic 
trial and these issues reflect real life in primary care.  A further point of debate is the criteria of 
airflow obstruction we were required to use in our assessments in order to be comparable with current 
UK guidance. Use of the fixed ratio tends to overestimate the prevalence of new cases of COPD 
compared with the lower limit of normal alternative criteria33 , particularly amongst older males. Use 
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of these criteria in the targeted arm attenuated the yield by about 25%; however it is unlikely that 
there would be any relative difference between the two arms if these criteria were applied to both. 
For the future, it would be useful to identify more efficient ways to uncover new cases. In our study, 
in order to identify one new case of COPD, screening questionnaires had to be provided to 21 extra 
patients. Algorithms derived from GP records might better predict new cases of COPD and allow 
more efficient targeting of invitations, but require further testing.34 Our sensitivity analyses also 
suggested that limiting to one postal reminder and targeting those aged 50+ might be less expensive 
with minimal loss in effectiveness. A postal-only approach would be nearly as effective and avoid the 
need for opportunistic administration during busy consultation times.  
Finally, before a national case finding programme could be recommended, the longer term effects of 
case-finding on health outcomes should be studied. The DIMCA programme in the Netherlands 
suggested that long-term prognosis might not be improved by screening.24 It would be important to 
establish whether earlier identification using our approach would lead to effective management and 
health gains which would outweigh the cost to the health service of the medications and management 
and the potential cost to the patient of having a “label” of COPD. Currently, there is insufficient 
evidence of this. 
In conclusion, in this well-established primary care system, routine practice identified few new cases. 
An active targeted approach is a highly effective and also cost-effective way to identify patients with 
undiagnosed clinically important COPD and has the potential to improve their health.  
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Table 1 Screening process assumptions and costs   
Process Assumption Source Cost per 
patient (£) 
Searches of patient records, screening and flagging notes with prompts 
Running the search 20 minute of practice manager time per 
practice 
Estimate from 
trial  
0.01 
Screening patient list 1 minute of GP time per patient selected NIHR costing 
report 
3.20 
Attaching prompts 15 seconds of administration time per patient 
record  
Estimate from 
trial 
0.94 
Total 4.14 
Invitation letters and questionnaires 
Drafting/approving 
letter  
1 hour of practice manager time per practice 
per mailout 
NIHR costing 
report 
0.05 
Administering mail-
merge x 3 
2 hours of administration time per practice per 
mailout 
NIHR costing 
report 
0.08 
Administering the 
postal questionnaires  
1.8 minutes of administration time per letter 
sent, plus stationery cost 
NIHR costing 
report 
0.67 
Stationery cost for 
postal questionnaire 
6 sheets of headed note paper & letter head, 
stamp, envelope & prepaid return envelope 
NIHR costing 
report 
1.74 
Total per questionnaire/reminder 2.55 
Completing the 
questionnaire in-clinic  
6 sheets of headed notepaper & 1 minute of 
GP time per questionnaire completed in clinic 
NIHR costing 
report, estimate 
from trial  
3.84 
Processing 
questionnaires and 
allocating 
appointment times 
30 minutes of administration time per 
questionnaire completed 
Estimate from 
trial, NIHR 
costing report 
11.23 
Appointment booking 
Book appointments 10 minutes plus stamp, letter and envelope for 
100% of appointments and text message for 
49% of appointments 
Estimate from 
trial , NIHR 
costing report 
4.32 
Proportion of patients 
that cancelled or 
rebooked 
All booked appointments divided by 
appointment attended 
 1.91 
Total per appointment 8.26 
Spirometry 
Staff costs 50 minutes clinical support worker time, 3 
minutes of reception time  
Estimate from 
trial 
22.04 
Training 4 weeks training, plus 2-day workshop, 1-day 
refresher course. Annual cost, assuming 372 
tests per year and 3-yearly reassessment 
Estimate from 
trial 
  4.33 
Room costs 50 minutes per appointment (allowing for 
DNAs) 
Estimate from 
trial 
12.55 
Travel costs Average 2.85 miles per attendance, 40p per 
mile 
Estimate from 
trial 
  1.14 
Equipment Use of spirometer and laptop. Single use of 
mouthpiece, spacer and salbutamol. 
Estimate from 
trial 
10.87 
Total  50.95 
DNA = Did not attend. NIHR costing report: http://www.crn.nihr.ac.uk/resources/resource-template/ (Accessed 11th 
August 2015) 
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Table 2 Baseline characteristics of randomised general practices  
 Targeted case finding Routine care 
 
Practice characteristics   
Total practices 27 27 
Practice list size 5762 (3482) 5811 (3451) 
IMD score 35.2(25.0,51.9) 36.0 (19.7,46.3) 
% white patients 80.5 (20.5) 79.1 (21.9) 
% age 45+ years 38.5 (34.2,43.4) 38.2 (33.1,43.4) 
Diagnosed prevalence of COPD (%) 1.6 (0.6) 1.7 (0.7) 
   
Patient characteristics   
Total patients 32,789† 42,029 
Sex (male) 17,864 (54.5) 21,659 (51.5) 
Age (Years) 55.3 (47.5, 65.5) 55.6 (47.6, 66.1) 
Ethnicity    
White 18,186 (55.5) 23,925 (56.9) 
Mixed 265 (0.8) 223 (0.5) 
Asian 1,742 (5.3) 2,044 (4.9) 
African Caribbean 1,220 (3.7) 1,025 (2.4) 
Other 591 (1.8) 353 (0.8) 
Missing 10,785 (32.9) 14,459 (34.4) 
Smoking status   
Never smoker 6,580 (20.1) 10,949 (26.1) 
Ex-smoker 13,857 (42.3) 16,685 (39.7) 
Current smoker 11,924 (36.4) 14,222 (33.8) 
Missing 428 (1.3) 173 (0.4) 
Comorbidities**   
Asthma 3117 (11.1%) 3834 (9.3%) 
Ischaemic heart disease 1881 (6.7%) 2341 (5.7%) 
Chest infection in previous 3 years 2694 (9.6%) 4377 (10.6%) 
Number of patients sharing 
household  
  
1 22,421 (68.4) 24,261 (57.7) 
2* 9,646 (29.4) 16,104 (38.3) 
3 or more* 722 (2.2) 1664 (4.0) 
 
Figures in this table are mean(SD), median(Q1,Q3) or n(%) as appropriate. 
*patients reside in the same household 
** From 22 targeted practices (28,025 patients) and 26 routine practices (41,100) with available data 
IMD=Index of multiple deprivation 
†results exclude 22 randomised patients who withdrew their data 
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Table 3 Effectiveness of active compared with opportunistic case finding‡ 
 Active 
N (%)  
Opportunistic 
N (%)  
Total 
N (%)  
Total patients approved by GP for contact 15378  15387  30,765  
Deceased by 12 months 93 (0.6)  92 (0.6)  185 (0.6)  
Left practice by 12 months 870 (5.7)  897 (5.8)  1,767 (5.7)  
Primary Outcome (NICE criteria)15          
COPD trial-identified (post BD FEV1/FVC 0.7)  662 (4.3)  189 (1.2)  851 (2.8)  
Additionally identified by GP  160 (1.0)  181 (1.2)  341 (1.1)  
Total COPD diagnosed  822 (5.4)  370 (2.4)  1,192 (3.9)  
Crude Risk difference (95% CI)  0.029 (0.025, 0.034)        
Crude Relative risk (95% CI)  2.22 (1.97, 2.51)        
Adjusted OR (95%CI)* 2.34 (2.06, 2.66) (p<0.001)   
Adjusted risk difference (95%CI)* † 0.029 (0.023, 0.036) (p<0.001)   
Characteristics of patients newly diagnosed 
through trial 
   
Total number 662 189 851 
Severity of airflow obstruction    
Mild (FEV1>80% predicted) 352 (53.2) 107 (56.6) 459 (53.9) 
Moderate (FEV1<80% and >50% predicted) 288 (43.5) 72 (38.1) 360 (42.3) 
Severe (FEV1<50% and >30% predicted) 19 (2.9) 10 (5.3) 29 (3.4) 
Very severe (FEV1<30% predicted) 3 (0.5) 0 (0.0) 3 (0.4) 
Breathlessness (MRC dyspnoea score Grade 3 
or more) 
172 (26.0) 59 (31.2) 231 (27.1) 
Current smoker 244 (36.9) 59 (29.6) 300 (35.3) 
Prior self-report of COPD/chronic 
bronchitis/emphysema 
74 (11.2) 18 (9.5) 92 (10.8) 
*adjusted for GP practices, IMD score of practice, patient age, patient ethnicity using logistic 
regression 
†obtained using estimate of RR of 2.30 (2.01, 2.58) from multilevel Poisson regression model with 
random effects and robust standard errors, together with the 2.4% baseline risk estimate from routine 
group  
BD=bronchodilator ‡results exclude 22 randomised patients who withdrew their data 
Table 4 Effectiveness of targeted case finding compared with routine care‡ 
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 Targeted case finding 
N (%)  
Routine care 
N (%)  
Total eligible patients 32789  42029  
Deceased  255 (0.8)  527 (1.3)  
Left practice  1,972 (6.0)  2,492 (5.9)  
Primary Outcome (NICE criteria)15       
COPD trial-identified (post BD FEV1/FVC <0.7)  851 (2.6)  -  
Additional patients identified by GP  427 (1.3)  337 (0.8)  
Total COPD newly diagnosed  1,278 (3.9)  337 (0.8)  
Crude risk difference (95% CI)  0.031 (0.029, 0.033)     
Crude relative risk (95% CI)  4.86 (4.32, 5.48)     
Adjusted OR (95%CI)* 7.45 (4.80, 11.55)(p<0.001)  
Adjusted risk difference (95%CI)*† 0.049 (0.030, 0.077)  
 
*adjusted for clustering of GP practices, IMD score of practice, patient age, patient ethnicity using 
multilevel logistic regression 
†obtained using adjusted estimate of RR (7.23 (4.10, 10.37)) from multilevel Poisson regression 
model with random effects and robust standard errors, together with the baseline risk estimate of 0.8% 
from routine group  
BD= bronchodilator 
‡results exclude 22 randomised patients who withdrew their data 
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Table 5 Results of the cost-effectiveness analysis with sensitivity analyses 
 Active vs routine care Opportunistic vs routine care 
Scenario New cases 
identified in 
the active 
arm* 
Difference 
in mean per 
patient 
costs (£) 
Adjusted 
difference in 
mean cases 
detected 
Cost per 
additional 
case 
detected 
(£) 
New cases 
identified in 
the 
opportunistic 
arm* 
Difference 
in mean 
per patient 
costs (£) 
Adjusted 
difference in 
mean cases 
detected 
Cost per 
additional 
case detected 
(£) 
Base case 822 (100%) 23.15 0.0696 333 370 (100%) 7.95 0.0211 376 
Including patient costs  23.64 0.0696 340  8.04 0.0211 381 
GP led model†  28.97 0.0696 416  9.47 0.0211 448 
Community model†  23.53 0.0696 338  8.05 0.0211 381 
Tariff model†  26.28 0.0696 378  8.77 0.0211 415 
Altering target groups:         
Ever smokers only 707 (86.0%) 23.10 0.0753 307 322 (87.0%) 7.69 0.0219 351 
Current smokers only 317 (38.6%) 21.30 0.0744 286 164 (44.3%) 7.29 0.0242 301 
Aged 65+  378 (46.0%) 26.31 0.1282 205 204 (55.1%) 9.53 0.0477 200 
Aged 60+ 534 (65.0%) 26.23 0.1089 241 264 (71.4%) 9.26 0.0380 244 
Aged 55+ 646 (78.6%) 25.69 0.1029 250 302 (81.6%) 9.00 0.0320 281 
Aged 50+ 733 (89.2%) 24.90 0.0941 265 336 (90.8%) 8.47 0.0291 291 
Aged 45+ 786 (95.6%) 23.99 0.0813 295 355 (95.9%) 8.26 0.0248 333 
Altering triggers for spirometry 
invite**: 
        
Cough & phlegm only  383 (46.6%) 17.36 0.0236 735 234 (63.2%) 6.25 0.0086 725 
Dyspnoea only 655 (79.7%) 20.66 0.0524 394 316 (85.4%) 7.33 0.0164 446 
Excluding wheeze 713 (86.7%) 21.46 0.0580 370 336 (90.8%) 7.49 0.0181 414 
Altering processes**         
3 month period for recruitment 786 (95.6%) 22.35 0.0658 340 311 (84.1%) 6.94 0.0143 484 
1 reminder 740 (90.0%) 21.59 0.0610 354 370 (100%) 7.95 0.0211 376 
0 reminders 589 (71.7%) 19.01 0.0441 431 370 (100%) 7.95 0.0211 376 
*raw numbers only, given as n (% of base cases identified)   
** alternative scenarios assume that additional patients are not diagnosed outside of the trial processes instead † details provided in appendix 4  
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Figure 1 Schema of TargetCOPD case finding RCT † 
 
 
 
 
†Note that search terms were applied to electronic health records in order to identify ever smokers, but any patients found to 
be never smokers were included in the primary analysis in order to maintain the pragmatic approach. 
 
After the randomisation level, values exclude 22 patients who withdrew their data.  
 
*% of all approved patients randomised to nested trial   **% of all eligible in cluster comparison 
 
 
